Skip to main content

Fiscal Wizard · Single-issue tearsheet

RDY / Jun 20, 2026 Run #7177

RDY

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Composite verdict

F 22.4 / 100
Bearish setup · Trend Following 11 drivers · 4 gates blocking
  • MACD Signal Cross
  • Elder Force Index
  • Multi Top/Bottom
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 46th of 85 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 18 signals100% Bear
Momentum Bearish 5Mean-reversion Neutral 48

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -85%
Asset value $452.81Earnings power value $413.86Price $13.29

Trading below its asset value ($452.81/share) — deep value, but check for a melting balance sheet.

Fundamentals Mixed

44.7 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Free Cash Flow Yield 100
Margin of Safety 0
Greenblatt EY 100
Cash Conversion 0
Return on Assets 77
Inventory Turnover 0

Technicals Bearish

0.1 / 100

Bearish setup leads (MACD Signal Cross, Elder Force Index, Multi Top/Bottom); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
MACD Signal Cross 8
Elder Force Index 11
Vortex Signal 15

Risk Gates

4 blocking 3 caution

4 guards active, 21 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for RDY.